Outcomes in COVID-19 ixekizumab studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -50% 1 32 Improvement, Studies, Patients Relative Risk Mortality -50% 1 32 RCTs -50% 1 32 Late -50% 1 32 Ixekizumab for COVID-19 c19early.org November 2025 Favorsixekizumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STRUCK Pimenta B.. (RCT) -50% 1.50 [0.29-7.81] death 3/16 2/16 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Late treatment -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk All studies -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk 1 ixekizumab COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors ixekizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STRUCK Pimenta B.. (RCT) -50% 1.50 [0.29-7.81] 3/16 2/16 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Late treatment -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk All studies -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk 1 ixekizumab COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Favors ixekizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STRUCK Pimenta B.. (RCT) -50% 1.50 [0.29-7.81] death 3/16 2/16 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Late treatment -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk All studies -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk 1 ixekizumab COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors ixekizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STRUCK Pimenta B.. (RCT) -50% 1.50 [0.29-7.81] death 3/16 2/16 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Late treatment -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk All studies -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk 1 ixekizumab COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors ixekizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STRUCK Pimenta B.. (RCT) -50% 1.50 [0.29-7.81] 3/16 2/16 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Late treatment -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk All studies -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk 1 ixekizumab COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Favors ixekizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STRUCK Pimenta B.. (RCT) -50% 1.50 [0.29-7.81] death 3/16 2/16 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Late treatment -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk All studies -50% 1.50 [0.29-7.81] 3/16 2/16 50% higher risk 1 ixekizumab COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors ixekizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STRUCK Pimenta B.. (RCT) -50% 1.50 [0.29-7.81] death 3/16 2/16 Improvement, RR [CI] Treatment Control STRUCK Pimenta B.. (RCT) 0% 1.00 [0.24-4.23] no improv. 3/16 3/16 Ixekizumab COVID-19 outcomes c19early.org November 2025 Favors ixekizumab Favors control